<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">Tumor growth</z:e> depends upon an adequate supply of oxygen and nutrients achieved through <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> and maintenance of an intact <z:e sem="disease" ids="C1658953" disease_type="Neoplastic Process" abbrv="">tumor vasculature</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Therapy with individual agents that target new vessel formation or existing vessels has suppressed <z:e sem="disease" ids="C0027659" disease_type="Neoplastic Process;Experimental Model of Disease" abbrv="">experimental tumor</z:e> growth, but rarely resulted in the eradication of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>We therefore tested the combined anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> activity of vasostatin and interferon-inducible protein-10 (IP-10), agents that differently target the <z:e sem="disease" ids="C1658953" disease_type="Neoplastic Process" abbrv="">tumor vasculature</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Vasostatin, a selective and direct inhibitor of endothelial cell proliferation, significantly reduced <z:e sem="disease" ids="C0006413" disease_type="Neoplastic Process" abbrv="BL">Burkitt tumor</z:e> growth and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> vessel density </plain></SENT>
<SENT sid="4" pm="."><plain>IP-10, an "angiotoxic" chemokine, caused vascular damage and focal <z:mp ids='MP_0001651'>necrosis</z:mp> in <z:e sem="disease" ids="C0006413" disease_type="Neoplastic Process" abbrv="BL">Burkitt tumors</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>When combined, vasostatin plus IP-10 reduced <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> more effectively than each agent alone, but complete <z:mp ids='MP_0010537'>tumor regression</z:mp> was not observed </plain></SENT>
<SENT sid="6" pm="."><plain>Microscopically, these <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> displayed focal <z:mp ids='MP_0001651'>necrosis</z:mp> and reduction in vessel density </plain></SENT>
<SENT sid="7" pm="."><plain>Combination therapy with the inhibitors of <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> vasostatin and IP-10 is effective in reducing the rate of <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> but fails to induce <z:mp ids='MP_0010537'>tumor regression</z:mp>, suggesting that curative treatment may require supplemental drugs targeting directly the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells </plain></SENT>
</text></document>